Last reviewed · How we verify

Shanghai WiseGain Medical Devices Co., Ltd. — Portfolio Competitive Intelligence Brief

Shanghai WiseGain Medical Devices Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Amlodipine, losartan potassium and hydrochlorothiazide Amlodipine, losartan potassium and hydrochlorothiazide phase 3 Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic) L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hanmi Pharmaceutical Company Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai WiseGain Medical Devices Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shanghai WiseGain Medical Devices Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-wisegain-medical-devices-co-ltd. Accessed 2026-05-17.

Related